Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age

References

• Global Polio Eradication Initiative, World Health Organization. Polio endgame strategy 2019-2023. Eradication, integration, certification and containment. [accessed 2021 June 30]. http://polioeradication.org/wp-content/uploads/2019/06/english-polio-endgame-strategy.pdf .
   Google Scholar
• World Health Organization. Polio vaccines: WHO position paper – March, 2016. Wkly Epidemiol Rec. 2016;91(12):145–11.
   PubMedGoogle Scholar
• Chard AN, Datta SD, Tallis G, Burns CC, Wassilak SGF, Vertefeuille JF, Zaffran M. Progress toward polio eradication — worldwide, January 2018–March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(25):784–89. doi:10.15585/mmwr.mm6925a4.
   PubMed Web of Science ®Google Scholar
• Global Polio Eradication Initiative. GPEI polio today WPV reports. [accessed 2021 June 30]. https://polioeradication.org/polio-today/polio-now/this-week/ .
   Google Scholar
• Jorba J, Diop OM, Iber J, Henderson E, Zhao K, Quddus A, Sutter R, Vertefeuille JF, Wenger J, Wassilak SGF, et al. Update on vaccine-derived poliovirus outbreaks — worldwide, January 2018–June 2019. MMWR Morb Mortal Wkly Rep. 2019;68(45):1024–28. doi:10.15585/mmwr.mm6845a4.
   PubMed Web of Science ®Google Scholar
• World Health Organization Strategic Advisory Group of Experts. Meeting of the strategic advisory group of experts on immunization, October 2020 – conclusions and recommendations. no. 48. Wkly Epidemiol Rep 2020;95:585–608.
   Google Scholar
• Okayasu H, Sutter RW, Jafari HS, Takane M, Aylward RB. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis. 2014;210(suppl_1):S459–64. doi:10.1093/infdis/jiu128.
   PubMed Web of Science ®Google Scholar
• Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine. 2016;34:1975–85. doi:10.1016/j.vaccine.2014.11.015.
   PubMed Web of Science ®Google Scholar
• Yan S, Chen H, Zhang Z, Chang S, Xiao Y, Luo L, Zhang Z, Sun L, Chen X, Yang Y, et al. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China. Vaccine. 2020;38:6274–79. doi:10.1016/j.vaccine.2020.07.042.
   PubMed Web of Science ®Google Scholar
• Sanders BP, Edo-Matas D, Custers JH, Koldijk MH, Klaren V, Turk M, Luitjens A, Bakker WA, Uytdehaag F, Goudsmit J, et al. Per.C6® cells as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated poliovirus vaccine. Vaccine. 2013;31(5):850–56. doi:10.1016/j.vaccine.2012.10.070.
   PubMed Web of Science ®Google Scholar
• Sanders BP, Oakes Ide L, van Hoek V, Liu Y, Marissen W, Minor PD, Wimmer E, Schuitemaker H, Custers JH, Macadam A, et al. Production of high titer attenuated poliovirus strains on the serum-free PER.C6® cell culture platform for the generation of safe and affordable next generation IPV. Vaccine. 2015;33(48):6611–16. doi:10.1016/j.vaccine.2015.10.091.
   PubMed Web of Science ®Google Scholar
• Bockstal V, Tiemessen MM, Achterberg R, Van Wordragen C, Knaapen AM, Serroyen J, Marissen WE, Schuitemaker H, Zahn R. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model. Vaccine. 2018;36(46):6979–87. doi:10.1016/j.vaccine.2018.09.068.
   PubMed Web of Science ®Google Scholar
• Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther. 1998;9(13):1909–17. doi:10.1089/hum.1998.9.13-1909.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Launay O, Lelievre JD, Lacabaratz C, Grande S, Goldstein N, Robinson C, Gaddah A, Bockstal V, Wiedemann A, et al. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): A randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2021;21(4):493–506. doi:10.1016/S1473-3099(20)30476-X.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–201. doi:10.1056/NEJMoa2101544.
   PubMed Web of Science ®Google Scholar
• Custers J, Kim D, Leyssen M, Gurwith M, Tomaka F, Robertson J, Heijnen E, Condit R, Shukarev G, Heerwegh D, et al. Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment. Vaccine. 2021;39:3081–101. doi:10.1016/j.vaccine.2020.09.018.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Leroux-Roels G, Shukarev G, Schuitemaker H, Cahill C, de Rooij R, Struijs M, van Zeeburg H, Jacquet JM. Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: A phase 1 randomized controlled trial in adults. Hum Vaccin Immunother. 2021;17(5):1366–73. doi:10.1080/21645515.2020.1812315.
   PubMed Web of Science ®Google Scholar
• Liao G, Li R, Li C, Sun M, Li Y, Chu J, Jiang S, Li Q. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, positive-controlled trial. J Infect Dis. 2012;205(2):237–43. doi:10.1093/infdis/jir723.
   PubMed Web of Science ®Google Scholar
• Liao G, Li R, Li C, Sun M, Jiang S, Li Y, Mo Z, Xia J, Xie Z, Che Y, et al. Phase 3 trial of a Sabin strain–based inactivated poliovirus vaccine. J Infect Dis. 2016;214(11):1728–34. doi:10.1093/infdis/jiw433.
   PubMed Web of Science ®Google Scholar
• Okada K, Miyazaki C, Kino Y, Ozaki T, Hirose M, Ueda K. Phase II and III clinical studies of diphtheria-tetanus-acellular pertussis vaccine containing inactivated polio vaccine derived from Sabin strains (DTaP-sIPV). J Infect Dis. 2013;208(2):275–83. doi:10.1093/infdis/jit155.
   PubMed Web of Science ®Google Scholar
• Verdijk P, Rots NY, van Oijen MG, Weldon WC, Oberste MS, Okayasu H, Sutter RW, Bakker WA. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. Vaccine. 2014;32:4938–44. doi:10.1016/j.vaccine.2014.07.029.
   PubMed Web of Science ®Google Scholar
• Nakano T, Sumino S, Takanami Y, Mitsuya N, Nakatome K. A phase 2 study of a combined diphtheria-tetanus-acellular pertussis vaccine with a Sabin-derived inactivated poliovirus vaccine in children. Hum Vaccin Immunother. 2018;14(12):2940–49. doi:10.1080/21645515.2018.1504538.
   PubMed Web of Science ®Google Scholar
• Chu K, Ying Z, Wang L, Hu Y, Xia J, Chen L, Wang J, Li C, Zhang Q, Gao Q, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial. Vaccine. 2018;36:6782–89. doi:10.1016/j.vaccine.2018.09.023.
   PubMed Web of Science ®Google Scholar
• Hu Y, Wang J, Zeng G, Chu K, Jiang D, Zhu F, Ying Z, Chen L, Li C, Zhu F, et al. Immunogenicity and safety of a Sabin strain–based inactivated polio vaccine: A phase 3 clinical trial. J Infect Dis. 2019;220(10):1551–57. doi:10.1093/infdis/jiy736.
   PubMed Web of Science ®Google Scholar
• Tang R, Li G, Zhang C, Zhi H, Zhu J, Wang J, Liang Q, Hu Y, Li C. A phase ΙΙ, randomized, controlled trial to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine. Hum Vaccin Immunother. 2020;16(11):2641–48. doi:10.1080/21645515.2020.1745593.
   PubMed Web of Science ®Google Scholar
• Cramer JP, Jimeno J, Han HH, Lin S, Hartmann K, Borkowski A, Saez-Llorens X. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial. Vaccine. 2020;38:5313–23. doi:10.1016/j.vaccine.2020.05.081.
   PubMed Web of Science ®Google Scholar
• Capeding MR, Gomez-Go GD, Oberdorfer P, Borja-Tabora C, Bravo L, Carlos J, Tangsathapornpong A, Uppala R, Laoprasopwattana K, Yang Y, et al. Safety and immunogenicity of a new inactivated polio vaccine made from Sabin strains: A randomized, double-blind, active-controlled, phase 2/3 seamless study. J Infect Dis. 2020. doi:10.1093/infdis/jiaa770.
   Google Scholar
• Piniaeva A, Ignatyev G, Kozlovskaya L, Ivin Y, Kovpak A, Ivanov A, Shishova A, Antonova L, Khapchaev Y, Feldblium I, et al. Immunogenicity and safety of inactivated Sabin-Strain polio vaccine “PoliovacSin”: Clinical trials phase I and II. Vaccines (Basel). 2021;9(6):565. doi:10.3390/vaccines9060565.
   PubMed Web of Science ®Google Scholar
• World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–94. doi:10.1001/jama.2013.281053.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Guideline for good clinical practice E6(R2). Step 5. [ accessed 2021 June 30]. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf .
   Google Scholar
• World Health Organization & WHO Expert Committee on Biological Standardization. WHO Expert Committee on Biological Standardization, sixty-fifth report. World Health Organ Tech Rep Ser. 2015;1–262. [Accessed 2022 February 28]. https://apps.who.int/iris/handle/10665/173739 .
   Web of Science ®Google Scholar
• Crawt L, Atkinson E, Tedcastle A, Pegg E, Minor P, Cooper G, Rigsby P, Martin J Report on the WHO collaborative study to establish the 1st International Standard for Sabin inactivated polio vaccine (sIPV). [ accessed 2018 October 29 – November 2]. https://cdn.who.int/media/docs/default-source/biologicals/bs-documents-(ecbs)/2019-documents/bs.2018.2338_sipv_is_collaborative_study_report_version.pdf?sfvrsn=9b150f78_5&download=true .
   Google Scholar
• Jia S, Tang R, Li G, Hu Y, Liang Q. The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines. BMC Infect Dis. 2020;20(1):641. doi:10.1186/s12879-020-05348-1.
   PubMed Web of Science ®Google Scholar
• Voysey M, Kelly DF, Fanshawe TR, Sadarangani M, O’-Brien KL, Perera R, Pollard AJ. The influence of maternally derived antibody and infant age at vaccination on infant vaccine responses: An individual participant meta-analysis. JAMA Pediatr. 2017;171(7):637–46. doi:10.1001/jamapediatrics.2017.0638.
   PubMed Web of Science ®Google Scholar
• Bravo LC, Carlos JC, Gatchalian SR, Montellano MEB, Tabora C, Thierry-Carstensen B, Tingskov PN, Sorensen C, Wachmann H, Bandyopadhyay AS, et al. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age. Vaccine. 2020;38(3):530–38. doi:10.1016/j.vaccine.2019.10.064.
   PubMed Web of Science ®Google Scholar